|
Market Closed -
Nasdaq
01:30:00 01/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 522.81 USD | -0.74% |
|
+1.52% | +15.32% |
| 28/09 | UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating | MT |
| 23/09 | TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 571.39 | +8.48% | 28 | ||||||
| 1,328.83 | +12.17% | 29 | ||||||
| 279.27 | +4.37% | 22 | ||||||
| 278.86 | +5.91% | 28 | ||||||
| 155.68 | +4.29% | 25 | ||||||
| 375.34 | +7.46% | 19 | ||||||
| 152.22 | +5.11% | 22 | ||||||
| 210.66 | +28.35% | 23 | ||||||
| 390.94 | -7.72% | 29 | ||||||
| 158.65 | +4.87% | 26 | ||||||
| 307.56 | +22.22% | 23 | ||||||
| 28.88 | +0.54% | 26 | ||||||
| 66.71 | +6.12% | 24 | ||||||
| 979.36 | +13.24% | 14 | ||||||
| 21.75 | +17.18% | 21 | ||||||
| 94.06 | +31.61% | 24 | ||||||
| 119.56 | -41.24% | 18 | ||||||
| 850.88 | +13.37% | 26 | ||||||
| 154.21 | +12.24% | 14 | ||||||
| 8,870 | +45.51% | 15 | ||||||
| Average | 769.74 | +9.70% | 23 | ||||||
| Weighted average by Cap. | 602.86 | +8.71% | 25 |
- Stock Market
- Stocks
- VRTX Stock
- Sector Vertex Pharmaceuticals Incorporated
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
